LOX-1 in Atherosclerosis and Myocardial Ischemia: Biology, Genetics, and Modulation

Journal of the American College of Cardiology

Volumn 69, Issue 22, 2017, Pages 2759-2768

  Pothineni, Naga Venkata K ^a,b   Karathanasis, Sotirios K ^c   Ding, Zufeng ^a,b   Arulandu, Arockiasamy ^b,d   Varughese, Kottayil I ^b   Mehta, Jawahar L ^a,b  

^a CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c MEDIMMUNE   (United States)

^d INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Italy)

Author keywords

coronary artery disease; endothelial cells; low density lipoprotein; LOX 1 blockers; myocardial infarction; reactive oxygen species

Indexed keywords

BERBERINE; BERGAMOT OIL; CURCUMIN; ELLAGIC ACID; FLAVONOID; GINKGO BILOBA EXTRACT; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1; PTEROSTILBENE; RESVERATROL; SHOGAOL; TANSHINONE IIA; TETRAMETHYLPYRAZINE; OLR1 PROTEIN, HUMAN;

3' UNTRANSLATED REGION; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; G501C GENE; GENE; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; HEART MUSCLE ISCHEMIA; HUMAN; LINKAGE DISEQUILIBRIUM BLOCK; PRIORITY JOURNAL; REVIEW; SELAGINELLA; SINGLE NUCLEOTIDE POLYMORPHISM; GENETIC POLYMORPHISM; GENETICS; METABOLISM;

ATHEROSCLEROSIS; HUMANS; MYOCARDIAL ISCHEMIA; POLYMORPHISM, GENETIC; SCAVENGER RECEPTORS, CLASS E;

EID: 85019720055     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2017.04.010     Document Type: Review

References (48)

1. Sawamura, T., Kume, N., Aoyama, T., et al. An endothelial receptor for oxidized low-density lipoprotein. Nature 386 (1997), 73–77.
2. Mehta, J.L., Chen, J., Hermonat, P.L., Romeo, F., Novelli, G., Lectin-like, oxidized low-density lipoprotein receptor-1 (LOX-1): a critical player in the development of atherosclerosis and related disorders. Cardiovasc Res 69 (2006), 36–45.
3. Kume, N., Murase, T., Moriwaki, H., et al. Inducible expression of lectin-like oxidized LDL receptor-1 in vascular endothelial cells. Circ Res 83 (1998), 322–327.
4. Pant, S., Deshmukh, A., Gurumurthy, G.S., et al. Inflammation and atherosclerosis—revisited. J Cardiovasc Pharmacol Ther 19 (2014), 170–178.
5. Chen, M., Nagase, M., Fujita, T., Narumiya, S., Masaki, T., Sawamura, T., Diabetes enhances lectin-like oxidized LDL receptor-1 (LOX-1) expression in the vascular endothelium: possible role of LOX-1 ligand and AGE. Biochem Biophys Res Commun 287 (2001), 962–968.
6. Tsimikas, S., Brilakis, E.S., Miller, E.R., et al. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med 353 (2005), 46–57.
7. Mehta, J.L., Sanada, N., Hu, C.P., et al. Deletion of LOX-1 reduces atherogenesis in LDLR knockout mice fed high cholesterol diet. Circ Res 100 (2007), 1634–1642.
8. Ryoo, S., Bhunia, A., Chang, F., Shoukas, A., Berkowitz, D.E., Romer, L.H., OxLDL-dependent activation of arginase II is dependent on the LOX-1 receptor and downstream RhoA signaling. Atherosclerosis 214 (2011), 279–287.
9. Ding, Z., Liu, S., Wang, X., et al. LOX-1, mtDNA damage, and NLRP3 inflammasome activation in macrophages: implications in atherogenesis. Cardiovasc Res 103 (2014), 619–628.
10. Hinagata, J., Kakutani, M., Fujii, T., et al. Oxidized LDL receptor LOX-1 is involved in neointimal hyperplasia after balloon arterial injury in a rat model. Cardiovasc Res 69 (2006), 263–271.
11. Ishigaki, Y., Katagiri, H., Gao, J., et al. Impact of plasma oxidized low-density lipoprotein removal on atherosclerosis. Circulation 118 (2008), 75–83.
12. Wang, X., Khaidakov, M., Guo, Z., Ding, Z., He, Q., Mehta, J.L., LOX-1 deletion limits cardiac angiogenesis in mice given angiotensin II. Cardiovasc Drugs Ther 28 (2014), 441–446.
13. Hu, C., Dandapat, A., Sun, L., et al. LOX-1 deletion decreases collagen accumulation in atherosclerotic plaque in low-density lipoprotein receptor knockout mice fed a high-cholesterol diet. Cardiovasc Res 79 (2008), 287–293.
14. Besler, C., Heinrich, K., Rohrer, L., et al. Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease. J Clin Invest 121 (2011), 2693–2708.
15. Li, D., Williams, V., Liu, L., et al. Expression of lectin-like oxidized low-density lipoprotein receptors during ischemia-reperfusion and its role in determination of apoptosis and left ventricular dysfunction. J Am Coll Cardiol 41 (2003), 1048–1055.
16. Lu, J., Wang, X., Wang, W., et al. LOX-1 abrogation reduces cardiac hypertrophy and collagen accumulation following chronic ischemia in the mouse. Gene Ther 19 (2012), 522–531.
17. Hayashida, K., Kume, N., Murase, T., et al. Serum soluble lectin-like oxidized low-density lipoprotein receptor-1 levels are elevated in acute coronary syndrome: a novel marker for early diagnosis. Circulation 112 (2005), 812–818.
18. Tatsuguchi, M., Furutani, M., Hinagata, J., et al. Oxidized LDL receptor gene (OLR1) is associated with the risk of myocardial infarction. Biochem Biophys Res Commun 303 (2003), 247–250.
19. Predazzi, I.M., Norata, G.D., Vecchione, L., et al. Association between OLR1 K167N SNP and intima media thickness of the common carotid artery in the general population. PLoS One, 7, 2012, e31086.
20. Au, A., Griffiths, L.R., Cheng, K.K., Wee Kooi, C., Irene, L., Keat Wei, L., The influence of OLR1 and PCSK9 gene polymorphisms on ischemic stroke: evidence from a meta-analysis. Sci Rep, 5, 2015, 18224.
21. Xu, X., Hou, X., Liang, Y., et al. The gene polymorphism of LOX1 predicts the incidence of LVH in patients with essential hypertension. Cell Physiol Biochem 33 (2014), 88–96.
22. Biocca, S., Falconi, M., Filesi, I., et al. Functional analysis and molecular dynamics simulation of LOX-1 K167N polymorphism reveal alteration of receptor activity. PLoS One, 4, 2009, e4648.
23. Mango, R., Clementi, F., Borgiani, P., et al. Association of single nucleotide polymorphisms in the oxidised LDL receptor 1 (OLR1) gene in patients with acute myocardial infarction. J Med Genet 40 (2003), 933–936.
24. Biocca, S., Filesi, I., Mango, R., et al. The splice variant LOXIN inhibits LOX-1 receptor function through hetero-oligomerization. J Mol Cell Cardiol 44 (2008), 561–570.
25. Mango, R., Biocca, S., del Vecchio, F., et al. In vivo and in vitro studies support that a new splicing isoform of OLR1 gene is protective against acute myocardial infarction. Circ Res 97 (2005), 152–158.
26. Guo, X., Xiang, Y., Yang, H., Yu, L., Peng, X., Guo, R., Association of the LOX-1 rs1050283 polymorphism with risk for atherosclerotic cerebral infarction and its effect on sLOX-1 and LOX-1 expression in a Chinese population. J Atheroscler Thromb, 2016 Nov 12 [E-pub ahead of print].
27. Feng, T.Y., Shan, H.W., Lang, R., Associations between lectin-like, oxidized low-density lipoprotein receptor-1 G501C and 3′-UTR-C188T polymorphisms with coronary artery disease: a meta-analysis. Int J Clin Exp Med 8 (2015), 9275–9282.
28. Hou, X.W., Yang, R.Q., Zhong, Y.G., Gao, W., Sun, S.P., Wang, N.F., G501C polymorphism of the oxidized LDL receptor gene is associated with albuminuria in Chinese essential hypertension patients. Genet Mol Res 10 (2011), 2710–2717.
29. Palmieri, V.O., Coppola, B., Grattagliano, I., et al. Oxidized LDL receptor 1 gene polymorphism in patients with metabolic syndrome. Eur J Clin Invest 43 (2013), 41–48.
30. Bocchia, M., Galimberti, S., Aprile, L., et al. Genetic predisposition and induced pro-inflammatory/pro-oxidative status may play a role in increased atherothrombotic events in nilotinib treated chronic myeloid leukemia patients. Oncotarget 7 (2016), 72311–72321.
31. Mehta, J.L., Chen, J., Yu, F., Li, D.Y., Aspirin inhibits ox-LDL-mediated LOX-1 expression and metalloproteinase-1 in human coronary endothelial cells. Cardiovasc Res 64 (2004), 243–249.
32. Xu, S., Liu, Z., Huang, Y., et al. Tanshinone II-A inhibits oxidized LDL-induced LOX-1 expression in macrophages by reducing intracellular superoxide radical generation and NF-κB activation. Transl Res 160 (2012), 114–124.
33. Kang, B.Y., Khan, J.A., Ryu, S., Shekhar, R., Seung, K.B., Mehta, J.L., Curcumin reduces angiotensin II-mediated cardiomyocyte growth via LOX-1 inhibition. J Cardiovasc Pharmacol 55 (2010), 417–424.
34. Ou, H.C., Lee, W.J., Lee, I.T., et al. Ginkgo biloba extract attenuates oxLDL-induced oxidative functional damages in endothelial cells. J Appl Physiol 106 (2009), 1674–1685.
35. Wang, G.F., Shi, C.G., Sun, M.Z., et al. Tetramethylpyrazine attenuates atherosclerosis development and protects endothelial cells from ox-LDL. Cardiovasc Drugs Ther 27 (2013), 199–210.
36. Li, H., Xia, N., Förstermann, U., Cardiovascular effects and molecular targets of resveratrol. Nitric Oxide 26 (2012), 102–110.
37. Nishizuka, T., Fujita, Y., Sato, Y., et al. Procyanidins are potent inhibitors of LOX-1: a new player in the French Paradox. Proc Jpn Acad Ser B Phys Biol Sci 87 (2011), 104–113.
38. Lee, W.J., Ou, H.C., Hsu, W.C., et al. Ellagic acid inhibits oxidized LDL-mediated LOX-1 expression, ROS generation, and inflammation in human endothelial cells. J Vasc Surg 52 (2010), 1290–1300.
39. Bao, M., Lou, Y., Flavonoids from seabuckthorn protect endothelial cells (EA.hy926) from oxidized low-density lipoprotein induced injuries via regulation of LOX-1 and eNOS expression. J Cardiovasc Pharmacol 48 (2006), 834–841.
40. Zhang, L., Zhou, G., Song, W., et al. Pterostilbene protects vascular endothelial cells against oxidized low-density lipoprotein-induced apoptosis in vitro and in vivo. Apoptosis 17 (2012), 25–36.
41. Wang, Y.K., Hong, Y.J., Yao, Y.H., et al. 6-Shogaol protects against oxidized LDL-induced endothelial injuries by inhibiting oxidized LDL-evoked LOX-1 signaling. Evid Based Complement Alternat Med, 2013, 2013, 503521.
42. Huang, Z., Dong, F., Li, S., et al. Berberine-induced inhibition of adipocyte enhancer-binding protein 1 attenuates oxidized low-density lipoprotein accumulation and foam cell formation in phorbol 12-myristate 13-acetate-induced macrophages. Eur J Pharmacol 690 (2012), 164–169.
43. Zhang, W.F., Xu, Y.Y., Xu, K.P., et al. Inhibitory effect of selaginellin on high glucose-induced apoptosis in differentiated PC12 cells: role of NADPH oxidase and LOX-1. Eur J Pharmacol 694 (2012), 60–68.
44. Mollace, V., Ragusa, S., Sacco, I., et al. The protective effect of bergamot oil extract on lecitine-like oxyLDL receptor-1 expression in balloon injury-related neointima formation. J Cardiovasc Pharmacol Ther 13 (2008), 120–129.
45. Francone, O.L., Tu, M., Royer, L.J., et al. The hydrophobic tunnel present in LOX-1 is essential for oxidized LDL recognition and binding. J Lipid Res 50 (2009), 546–555.
46. Falconi, M., Ciccone, S., D'Arrigo, P., et al. Design of a novel LOX-1 receptor antagonist mimicking the natural substrate. Biochem Biophys Res Commun 438 (2013), 340–345.
47. Thakkar, S., Wang, X., Khaidakov, M., et al. Structure-based design targeted at LOX-1, a receptor for oxidized low-density lipoprotein. Sci Rep, 5, 2015, 16740.
48. Iwamoto, S., Nishimichi, N., Tateishi, Y., et al. Generation and characterization of chicken monoclonal antibodies against human LOX-1. MAbs 1 (2009), 357–363.